Significant correlations between severe fatty liver and risk factors for metabolic syndrome

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 12, 2007, Pages 2118-2123

  Hsiao, Pi Jung ^a   Kuo, Kung Kai ^a   Shin, Shyi Jang ^a   Yang, Yi Hsin ^a   Lin, Wen Yi ^a   Yang, Jeng Fu ^a   Chiu, Chao Chin ^a   Chuang, Wan Long ^b   Tsai, Tong Rong ^c   Yu, Ming Lung ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Metabolic syndrome; Non alcoholic fatty liver disease; Obesity; Ultrasonography

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATININE; GLUCOSE; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; RISK FACTOR; TAIWAN; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 36348948428     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04698.x     Document Type: Article

References (44)

1. Grant LM, Lisker-Melman M. Nonalcoholic fatty liver disease. Ann. Hepatol. 2004 3 : 93 9.
2. Medina J, Fernandez-Salazar LI, Garcia-Buey L, Moreno-Otero R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 2004 27 : 2057 66.
3. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002 123 : 1705 25.
4. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003 37 : 1202 19.
5. Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004 40 : 820 6.
6. Zafrani ES. Non-alcoholic fatty liver disease: an emerging pathological spectrum. Virchows Arch. 2004 444 : 3 12.
7. Green RM. NASH - hepatic metabolism and not simply the metabolic syndrome. Hepatology 2003 38 : 14 17.
8. den Boer M, Voshol PJ, Kuipers F, Havekes LM, Romijn JA. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler. Thromb. Vasc. Biol. 2004 24 : 644 9.
9. Quinn SF, Gosink BB. Characteristic sonographic signs of hepatic fatty infiltration. AJR Am. J. Roentgenol. 1985 145 : 753 5.
10. Saadeh S, Younossi ZM, Remer EM et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002 123 : 745 50.
11. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br. Med. J. (Clin. Res. Ed.) 1986 292 : 13 15.
12. Vehmas T, Kaukiainen A, Luoma K, Lohman M, Nurminen M, Taskinen H. Liver echogenicity: measurement or visual grading? Comput. Med. Imaging Graph. 2004 28 : 289 93.
13. Joseph AE, Saverymuttu SH, al-Sam S, Cook MG, Maxwell JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin. Radiol. 1991 43 : 26 31.
14. Day CP, James OF. Steatohepatitis: a tale of two 'hits'? Gastroenterology 1998 114 : 842 5.
15. George DK, Goldwurm S, MacDonald GA et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998 114 : 311 18.
16. Sanyal AJ, Campbell-Sargent C, Mirshahi F et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001 120 : 1183 92.
17. Emery MG, Fisher JM, Chien JY et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 2003 38 : 428 35.
18. Chalasani N, Gorski JC, Asghar MS et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with non-alcoholic steatohepatitis. Hepatology 2003 37 : 544 50.
19. dela Peña A, Leclercq I, Field J, George J, Jones B, Farrell, G. NF-κB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 2005 129 : 1663 74.
20. Mark J. Czaja liver injury in the setting of steatosis: crosstalk between adipokine and cytokine. Hepatology 2004 40 : 19 22.
21. Masaki T, Chiba C, Tatsukawa H et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-α in KK-Ay obese mice. Hepatology 2004 40 : 177 84.
22. Scatarige JC, Scott WW, Donovan PJ, Siegelman SS, Sanders RC. Fatty infiltration of the liver: ultrasonographic and computed tomographic correlation. J. Ultrasound Med. 1984 3 : 9 14.
23. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003 26 (Suppl. 1 S5 20.
24. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001 285 : 2486 97.
25. Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 2004 27 : 1182 6.
26. Anuurad E, Shiwaku K, Nogi A et al. The new BMI criteria for Asians by the regional office for the western pacific region of WHO are suitable for screening of overweight to prevent metabolic syndrome in elder Japanese workers. J. Occup. Health 2003 45 : 335 43.
27. Farrell GC. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? J. Gastroenterol. Hepatol. 2003 18 : 124 38.
28. Chitturi S, Farrell GC, George J. Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock? J. Gastroenterol. Hepatol. 2004 19 : 368 74.
29. Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004 40 : 1387 95.
30. Rattarasarn C, Leelawattana R, Soonthornpun S, Setasuban W, Thamprasit A. Gender differences of regional abdominal fat distribution and their relationships with insulin sensitivity in healthy and glucose-intolerant Thais. J. Clin. Endocrinol. Metab. 2004 89 : 6266 70.
31. Pi-Sunyer FX. The epidemiology of central fat distribution in relation to disease. Nutr. Rev. 2004 62 (7 Pt 2 S120 6.
32. Te Sligte K, Bourass I, Sels JP, Driessen A, Stockbrugger RW, Koek GH. Non-alcoholic steatohepatitis: review of a growing medical problem. Eur. J. Intern. Med. 2004 15 : 10 21.
33. Nammi S, Koka S, Chinnala KM, Boini KM. Obesity: an overview on its current perspectives and treatment options. Nutr. J. 2004 3 : 3.
34. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001 121 : 91 100.
35. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995 22 : 1714 19.
36. Wang Z, Hall SD, Maya JF, Li L, Asghar A, Gorski JC. Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br. J. Clin. Pharmacol. 2003 55 : 77 85.
37. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest. 1995 95 : 2409 15.
38. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumor necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001 48 : 206 11.
39. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ. 2005 172 : 899 905.
40. Suzuki K, Hayashi N, Sasaki Y et al. Dependence of ultrasonic attenuation of liver on pathologic fat and fibrosis: examination with experimental fatty liver and liver fibrosis models. Ultrasound Med. Biol. 1992 18 : 657 66.
41. Fusamoto H, Suzuki K, Hayashi N et al. Obesity and liver disease: evaluation of fatty infiltration of the liver using ultrasonic attenuation. J. Nutr Sci. Vitaminol. (Tokyo) 1991 37 (Suppl. S71 7.
42. Uygun A, Kadayifci A, Isik AT et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2004 19 : 537 44.
43. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2003 98 : 2485 90.
44. Lindor KD, Kowdley KV, Heathcote EJ et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004 39 : 770 8.